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Bacteria, such as Fusobacterium nucleatum, are pre-
sent in the tumor microenvironment. However, the
immunological consequences of intra-tumoral bac-
teria remain unclear. Here, we have shown that natu-
ral killer (NK) cell killing of various tumors is inhibited
in the presence of various F. nucleatum strains.
Our data support that this F. nucleatum-mediated
inhibition is mediated by human, but not by mouse
TIGIT, an inhibitory receptor present on all human
NK cells and on various T cells. Using a library of
F. nucleatum mutants, we found that the Fap2 pro-
tein of F. nucleatum directly interacted with TIGIT,
leading to the inhibition of NK cell cytotoxicity. We
have further demonstrated that tumor-infiltrating
lymphocytes expressed TIGIT and that T cell activ-
ities were also inhibited by F. nucleatum via Fap2.
Our results identify a bacterium-dependent, tumor-
immune evasion mechanism in which tumors exploit
the Fap2 protein of F. nucleatum to inhibit immune
cell activity via TIGIT.
INTRODUCTION
Bacteria colonize nearly all human body surfaces, and the bac-
terial communities of the gastro-intestinal tract are the most
abundant and complex (Tannock, 2008). This results in dynamic
interplay between a host and its resident microbes, and the gut
microbiota engage in a range of symbiotic interactions with the
humanmucosal immune system. There is an increasing appreci-344 Immunity 42, 344–355, February 17, 2015 ª2015 Elsevier Inc.ation that the gut microbiota might contribute to the pathogen-
esis of a range of human diseases. Coley’s toxin, a mixture of
killed bacteria including Streptococcus pyogenes and Serratia
marcescens, is considered a forerunner of modern immuno-
therapy. Coley’s toxin induces tumor regression in sarcomas
and other solid tumors. However, the relationship between bac-
teria and tumors is multifactorial. In particular, compelling links
are beginning to emerge between bacteria, inflammation, and
many malignancies, especially colon adenocarcinoma (Jobin,
2013; Sears and Garrett, 2014). Fusobacteria are often enriched
in patients with intestinal inflammation and cancer (Sobhani
et al., 2011; Strauss et al., 2011). It is still largely unknown why
certain tumors are enriched with particular bacteria and whether
such bacteria protect developing tumors from immune cell
attack.
F. nucleatum is a common oral anaerobic Gram-negative
rod and is primarily a periodontal bacterium. Interest in this
bacterium has increased in the last few years because of its
association with preterm birth (Han et al., 2004; Liu et al.,
2007), colon adenocarcinoma (Castellarin et al., 2012; Kostic
et al., 2013; Kostic et al., 2012; Rubinstein et al., 2013), and rheu-
matoid arthritis (Han and Wang, 2013; Te´moin et al., 2012).
F. nucleatum directly engages with the immune system. Fuso-
bacteria-associated Stillbirth and preterm births in mouse
models are Toll-like receptor-4 (TLR4)-dependent (Liu et al.,
2007). F. nucleatum also induces activation of intracellular
RIG-I receptor, a sensor of RNA viruses (Lee and Tan, 2014).
We have previously demonstrated that F. nucleatum directly in-
teracts with the NK cell receptor NKp46 and observed that this
interaction influences the outcome of F. nucleatum-mediated
periodontitis (Chaushu et al., 2012).
NK cells are part of the innate immune system, although recent
evidence suggests that they may also possess adaptive immune
properties (Vivier et al., 2011). NK cells kill tumors, viruses,
parasites and bacteria directly and indirectly (Koch et al., 2013).
NK cell activity is controlled by a balance of signals, delivered by
inhibitory and activating NK cell receptors (Koch et al., 2013).
There are several activating NK cell receptors that recognize
various ligands, which can be stress-induced, self-molecules,
viral components or tumor proteins (Koch et al., 2013; Seidel
et al., 2012). However, the exact mechanisms by which NK cells
recognize and eliminate tumors via activating receptors are not
well-understood, in part, because the tumor ligands of several
activating NK cell receptors are unknown. In contrast, the iden-
tity of the ligands recognized by inhibitory NK cell receptors is
very well defined. NK cells express a vast repertoire of inhibitory
receptors (Gardiner, 2008; Gonen-Gross et al., 2010; Koch et al.,
2013; Lankry et al., 2010; Seidel et al., 2012). Most of these inhib-
itory receptors belong to the KIR (Killer Inhibitory Receptors)
family, recognizing both classical and non-classical major histo-
compatibility complex (MHC) class I proteins (Koch et al., 2013;
Seidel et al., 2012). KIRs are stochastically expressed on the
NK cell surface, and thus NK cells in a given individual express
selected KIRs (Koch et al., 2013; Seidel et al., 2012). NK cells
also express additional inhibitory receptors that do not recognize
MHC class I proteins, such as CEACAM1, CD300a, and TIGIT
(T cell immunoglobulin and ITIM domain) (Koch et al., 2013;
Seidel et al., 2012).
The TIGIT receptor in humans is expressed on all NK cells, as
well as on other immune cells (Stanietsky et al., 2009). It recog-
nizes two very well-defined ligands: PVR and nectin2 (Stanietsky
et al., 2009). The recognition of these ligands leads to the delivery
of an inhibitory signal mediated by two motifs present in the
cytoplasmatic tail of TIGIT: the immunoreceptor tail tyrosine
(ITT)-like and the immunodominant tyrosine-based inhibitory
(ITIM) motifs (Liu et al., 2013; Stanietsky et al., 2013; Stanietsky
et al., 2009). In this study, we show that the Fap2 protein of
F. nucleatum inhibits tumor cell killing by immune cells via TIGIT.
RESULTS
F. nucleatum Adheres to Various Tumor Cells and
Inhibits NK Cell Cytotoxicity
F. nucleatum is found in human tumors, particularly colon adeno-
carcinoma tumors (Castellarin et al., 2012; Kostic et al., 2012). To
test whether the origin of the tumor (epithelial versus hematopoi-
etic) is important for F. nucleatum binding, we used FITC labeled
F. nucleatum ATCC strain 23726 (herein named 726) and exam-
ined its binding to the humanEpstein Bar Virus (EBV) transformed
B cell line 721.221, to the human erythroleukemic line K562, and
to the human colorectal carcinoma cell line RKO (Figure 1). We
observed that F. nucleatum bound all the tumor cell lines tested
(Figures 1A, 1D, and 1F). Using scanning electron microscopy
(SEM), we observed that NK cells (designated E for effectors)
clustered aroundF. nucleatum (designatedB for bacteria) coated
tumor cells (designated T for tumors) (Figure 1B).
We next tested whether F. nucleatum affects human NK cell
cytotoxicity. Primary activated human NK cells were incubated
for 5 hr with the various tumor cell lines that were pre-incubated
with or without F. nucleatum, in medium containing penicillin and
streptomycin (to ensure that F. nucleatum were not viable over
the course of the assay). In the presence of F. nucleatum, there
was a significant inhibition of NK cytotoxicity, irrespective ofthe human tumor cell line evaluated (Figures 1C, 1E, and 1G).
To test whether this effect was specific to this particular
F. nucleatum strain, we FITC labeled another F. nucleatum strain,
ATCC 49256 subsp. Vincentii (herein named 492). We confirmed
that it bound to 721.221 cells (Figure 1H) and observed that 492
also inhibited human NK cell killing (Figure 1I). In contrast, the ur-
opathogenic Escherichia coli (UPEC) strain CFT073 did not
inhibit NK cell cytotoxicity (Figure 1I). Incubation of the various
cancer cell targets coated with the various F. nucleatum strains
did not affect NK cell interferon-g (IFN-g) and tumor necrosis fac-
tor-a (TNF-a) secretion.
F. nucleatum Interacts with TIGIT
F. nucleatum-mediated inhibition of NK cell killing was observed
when several cell lines were used and was reproducible using
bulk primary activated human NK cells obtained from various
donors. Consequently, we hypothesized that F. nucleatummight
interact with an inhibitory NK cell receptor which is expressed on
the entire NK cell population and whose expression is conserved
across different individuals. As far as we know, TIGIT, (but not for
example the KIR receptors), is the only NK inhibitory receptor
which uniquely meets these requirements (Stanietsky et al.,
2009). To test whether F. nucleatum interacts with TIGIT, we
used a reporter system that we had previously generated (Sta-
nietsky et al., 2009). Murine thymoma BW cells were transfected
with a chimeric TIGIT protein in which the extracellular portion of
human TIGIT (hTIGIT) is fused to themouse zeta chain of the CD3
complex (Figure 2A, left). In this reporter system, if TIGIT is bound
and triggered by a specific ligand, then mouse IL-2 is secreted.
Thus, it reports both on the binding and on the functionality of
these interactions. We previously used this system to demon-
strate that both PVR and nectin2 are ligands for human and
mouse TIGIT (Stanietsky et al., 2013; Stanietsky et al., 2009).
As a control, we used BW cells expressing NKp30 fused to the
mouse zeta chain of the CD3 complex (Figure 2A, right). The
two reporter cells (BW hTIGIT and BW NKp30), as well as
the parental BW cells, were incubated with the 726 strain. Mouse
interleukin-2 (IL-2) was detected only upon incubation of 726
with BW hTIGIT (Figure 2B), indicating that F. nucleatum binds
to and activates hTIGIT. Because both TIGIT and DNAM1 bind
to a shared ligand, PVR (Stanietsky et al., 2009), we also pre-
pared another reporter cell line expressing the extracellular
portion of DNAM1 fused to mouse zeta chain of the CD3 com-
plex and observed that F. nucleatum did not interact with
DNAM1 (Figure 2B). The TIGIT binding was not restricted to
726 bacteria, because the 492 strain also activated BWhTIGIT
(Figure 2C). To test whether F. nucleatum could also bind mouse
TIGIT, the mouse TIGIT (mTIGIT) protein fused to the mouse zeta
chain was also expressed in BW cells (Figure 2D). However, no
IL-2 secretion was detected when the mTIGIT was used (Fig-
ure 2E). Thus, we concluded that F. nucleatum directly interacts
with human, but not mouse, TIGIT.
F. nucleatum Inhibits NK Cytotoxicity via TIGIT
To test whether F. nucleatum inhibits NK cell cytotoxicity via
TIGIT, we initially used the YTS ECO tumor cell line. The TIGIT-
negative YTS ECO cell line (Figure 3A) is an NK tumor cell line
that does not express any known NK inhibitory receptors. YTS
ECO kills only few cell lines, e.g., 721.221, which expressImmunity 42, 344–355, February 17, 2015 ª2015 Elsevier Inc. 345
Figure 1. F. nucleatum Protects Tumor
Cells from NK Cell Killing
(A, D, F, and H) Flow cytometry of FITC-labeled
F. nucleatum strains: 23726 (726) (A, D, and F) and
49256 (492) (H) binding to 721.221 (A and H), K562
(D), RKO (F). Figure shows one representative
staining out of four performed.
(B) SEM of human NK cells (Effector-E) incubated
with 721.221 (Target-T) cells coated with the 726
bacterial strain (Bacteria-B). The bacteria to
721.221 ratio was 600:1.
(C, E, G, and I) NK cytotoxicity assays were per-
formed on 35S-labeled 721.221 (C and I), K562 (E)
andRKO (G) cells incubatedwithout orwith the 726
strain (C, E, and G, designated +FN726), the 492
F. nucleatum strain (I, designated+FN492) andwith
UPEC strain CFT073 (I, designated +UPEC). The
bacteria to cells ratio was 600:1. The various cells
incubated with and without the bacteria were
incubated with primary activated human NK cells
for 5 hr and at various Effector to Target (E:T) ratios
indicated on the x axis. Figure shows one repre-
sentative experiment out of three performed. *p <
0.05 for (C), (E), (G), and (I). The error bars are
derived from triplicates.CD48, but not K562or RKO (which express little or noCD48). This
is because the 2B4 activating receptor, which recognizes CD48,
is the primary activating receptor that functions on the YTS ECO
cell line (Elias et al., 2014). To testwhether TIGIT inhibits YTSECO
cytotoxicity upon interaction with F. nucleatum-coated 721.221
cells, we expressed hTIGIT in YTS ECO cells (herein named
YTS hTIGIT, Figure 3A). As a control, we expressed the known
TIGIT ligand, PVR (Stanietsky et al., 2009), in 721.221 cells (Fig-
ure 3B). Next, we used the 721.221 and 721.221 PVR cells, incu-
bated with and without the 726 strain, in killing assays. Although
YTS ECO killing was not affected by the presence or absence of
F. nucleatum (Figure 3C), the killing of YTS ECO cells expressing
TIGIT was inhibited (Figure 3D). This inhibition was less pro-
nounced as compared to the PVR inhibition (Figure 3D). To test
whether F. nucleatum interacts with TIGIT at the same binding
site that mediates PVR binding, we used a blocking antibody
(#4) that was previously shown to block the hTIGIT interaction
with PVR (Stanietsky et al., 2009). 721.221 cells were incubated346 Immunity 42, 344–355, February 17, 2015 ª2015 Elsevier Inc.with YTS hTIGIT cells in the presence or
absence of F. nucleatum and in the pres-
ence or absence of anti-hTIGIT mAb #4.
Although mAb #4 partially blocked the
PVR-TIGIT interaction and consequently
partially restored YTS hTIGIT cytotoxicity,
it did not affect the F. nucleatum-
mediated inhibition (Figure 3E). Taken
together, these results suggest that
F. nucleatum binds hTIGIT at a binding
site distinct from that of human PVR.
TIGIT delivers its inhibitory signals via
ITIM and ITT motifs located in its cyto-
plasmic tail (Liu et al., 2013; Stanietsky
et al., 2013; Stanietsky et al., 2009). To
corroborate our observations and todemonstrate that F. nucleatum also exerts its inhibitory effect
on TIGIT through these motifs, we used two TIGIT truncation
stopmutants (Stanietsky et al., 2009). One was amutation at po-
sition 190 (named YTS hTIGIT stop 190, Figure 3F) lacking both
ITT and ITIM motifs. The second was a mutation at position 231,
in which a stop codon was inserted instead of the tyrosine resi-
due of the ITIM motif (named YTS hTIGIT stop 231, Figure 3F).
When either of the stop mutants were used, the F. nucleatum-
inhibition of TIGIT was abrogated (Figures 3G and 3H), suggest-
ing that TIGIT’s signaling inhibitory motifs are required for
F. nucleatum-mediated inhibition.
To demonstrate that F. nucleatum inhibits primary human NK
cytotoxicity via TIGIT, we incubated primary activated human
NK cells with 721.221 (Figure 4A) or with RKO cells (Figure 4B)
that were coated with or without F. nucleatum 726. NK cytotox-
icity was inhibited in the presence of the bacterium (Figures 4A
and 4B). To demonstrate that this inhibition was due to TIGIT,
we blocked the F. nucleatum interaction using a fusion protein
Figure 2. F. nucleatum Interacts with TIGIT
(A and D) Flow cytometry of parental BW cells of
BW cells transfected with human TIGIT fused to
mouse CD3 zeta chain (BW hTIGIT, A), of BW cells
transfected with human NKp30 fused to mouse
CD3 zeta chain (BW NKp30, A) and of BW cells
transfected with murine TIGIT fused tomouse CD3
zeta chain (BW mTIGIT, D). The various BW cells
were stained with the antibodies indicated above
the histograms. The gray filled histograms repre-
sent the control staining with the secondary anti-
body only. The various BW cells that are indicated
in the figure were incubated with F. nucleatum 726
(B and E) or with F. nucleatum 492 (C) at bacteria
to BW (B:BW) ratios that are indicated in the x axis.
Mouse IL-2 in the supernatants was determined
by ELISA. Figure shows one representative
experiment out of six performed. *p < 0.001 for (B),
(C), and (E). The error bars are derived from
triplicates.composed of the extracellular portion of hTIGIT fused to human
IgG1 (TIGIT-Ig). The F. nucleatum-mediated inhibition was
partially, but significantly, abolished when incubated in the pres-
ence of TIGIT-Ig, but not in the presence of a control Ig-fusion
protein (C-Ig, Figures 4A and 4B).
To demonstrate that F. nucleatum strains from human colon
tumors also inhibit NK cell cytotoxicity via TIGIT, we used
F. nucleatumstrains isolated fromhumancolonadenocarcinoma.
tumors. We next incubated 721.221 cells with two clinical strains
and then incubated the cells coated with the bacteria with YTS
hTIGIT cells (Figure 4C). Inhibition was observed with the
F. nucleatum strain clinical tumor isolate (CTI)-2 but not with
CTI-7 (Figure 4C). To further evaluate these results, we incubated
the clinical strains CTI-7 and CTI-2 with the BW hTIGIT reporterImmunity 42, 344–355,system described above. In agreement
with the killing results (Figure 4C), the
CTI-2 but not the CTI-7 directly activated
the BW hTIGIT cells (Figure 4D). Examina-
tion of the biological properties of these
clinical strains revealed that the CTI-7
strain that was unable to inhibit YTS
hTIGIT cytotoxicity (Figure 4C) and was
unable to interact with TIGIT (Figure 4D)
caused little or no hemagglutination (Fig-
ure 4E), whereas the CTI-2 strain, that in-
hibitedYTShTIGITcytotoxicity (Figure4C)
and that interacted with TIGIT (Figure 4D),
efficiently hemagglutinated human red
bloodcells (Figure 4E). Together, these re-
sults suggest thatF. nucleatum inhibitsNK
ell cytotoxicity via TIGIT and that this
inhibition is abrogated when F. nucleatum
is unable to agglutinate red blood cells.
The Fusobacterial Fap2 Protein
Interacts with TIGIT
To identify the F. nucleatum element that
interacts with TIGIT, we generated aF. nucleatum transposon-based insertion-inactivation mutant li-
brary (Coppenhagen-Glazer et al., 2015). Library mutants were
incubated with 721.221 cells and then with YTS hTIGIT cells,
and inhibition of cytotoxicity was assayed. Mutants unable to
cause inhibition of YTS hTIGIT cytotoxicity were tested for their
ability to agglutinate red blood cells as we observed that TIGIT
inhibition is abrogated in the absence of F. nucleatum hemagglu-
tination (Figures 4C–4E; examples are shown in Figures 5A and
5B). Two mutants (K50 and D22) that were unable to inhibit the
killing of YTS hTIGIT cells (Figure 5A) were also unable to cause
hemagglutination (Figure 5B). We FITC labeled the K50 and D22
mutants and tested their binding to various cells lines. While we
observed equal binding of the wild-type F. nucleatum and the
two mutants, K50 and D22, to 721.221 cells at all ratios ofFebruary 17, 2015 ª2015 Elsevier Inc. 347
Figure 3. F. nucleatum Inhibits YTS Cyto-
toxicity via TIGIT
(A) Flow cytometry of parental YTS ECO and
of YTS ECO cells expressing human TIGIT (YTS
hTIGIT) stained with anti-human TIGIT (gray empty
histograms) or with secondary control antibodies
only (black empty histograms).
(B) Flow cytometry of parental 721.221 and
of 721.221 cells expressing human PVR
(721.221hPVR) stained with anti-human PVR (gray
empty histograms) or with secondary control an-
tibodies only (black empty histograms). For (A)
and (B), one representative staining out of three
performed is shown.
(C and D) YTS ECO (C) and YTS hTIGIT (D) cells
were incubated with 35S-labeled 721.221 cells
(C and D) or with 721.221 hPVR cells (D). The
cells were pre-incubated or not with the
F. nucleatum 726 (designated 721.221+FN726).
The bacteria to cells ratio was 600:1. Incubation
was performed for 5 hr at the various YTS:Target
(E:T) ratios shown on the x axis. Figure shows
one representative experiment out of four per-
formed. *p < 0.05. The error bars are derived from
triplicates.
(E) YTS hTIGIT cells were incubated with or
without anti-human TIGIT mAb #4 (#4) and then
incubated with 35S-labeled 721.221 cells
(721.221), with 721.221 cells that were pre-incu-
bated with F. nucleatum 726 (721.221 FN726,
bacterium to cells ratio of 600:1) or with 721.221
cells expressing human PVR (721.221 hPVR). The
E:T ratio was 5:1 and incubations were performed
for 5 hr. *p < 0.05. The error bars are derived from
triplicates.
(F) Flow cytometry of parental YTS ECO cells
expressing TIGIT in which a STOP mutation was
inserted in amino acid number 190 (YTS hTIGIT
stop 190) or in amino acid 231 TIGIT (YTS hTIGIT
stop 231), stained with anti-human TIGIT (gray
empty histograms) or with secondary control
antibodies only (black empty histograms). Fig-
ure shows one representative experiment of three
performed.
(G and H) YTS hTIGIT stop 190 (G) and YTS hTIGIT
stop 231 (H) cells were incubated with 35S-labeled
721.221 cells that were pre-incubated with or
without F. nucleatum 726 (designated 721.221
FN726) or with 721.221 hPVR. The bacteria to cells ratio was 600:1. Incubation was performed for 5 hr at the various E:T ratios that are indicated in the x axis.
Figure shows one representative experiment out of two performed. The error bars are derived from triplicates.bacteria to human cells tested (Figure 5C and Figure S1, in Fig-
ure 5C we show the MOI of 600 and the unstained 721.221 cells
that also appear in Figure S1), the binding of themutants to K562
and RKO cells was less efficient (especially in the low bacteria to
human cell ratio) as compared to wild-type F. nucleatum (Fig-
ure S1). We therefore continued our assays with 721.221 cells
and observed that F. nucleatum-mediated inhibition of primary
activated human NK cell killing was lost with the K50 and D22
mutants (Figure 5D). Furthermore, the K50 and D22 mutants
were almost completely unable to activate the BW hTIGIT re-
porter system (Figure 5E).
In both K50 and D22 mutants, the transposon was inserted
into the gene encoding for the Fap2 protein of F. nucleatum
(Coppenhagen-Glazer et al., 2015). The insertions resulted in348 Immunity 42, 344–355, February 17, 2015 ª2015 Elsevier Inc.abolishment of the Fap2 protein expression as seen by Coomas-
sie gel staining (Figure 6A). To demonstrate that TIGIT and Fap2
interact with each other, we used two assays. We used an
ELISA-based assay in which the wild-type F. nucleatum and
the two mutants K50 and D22 were bound to plates and then
incubated with TIGIT-Ig. TIGIT interacted with the wild-type
F. nucleatum, but not with the two mutants or with other
bacteria, e.g., UPEC (Figure 6B). We also prepared a DNAM1-
Ig (CD227-Ig) fusion protein and showed that it did not interact
with the 726 bacterium (Figure 6B). Finally, we isolated vesicles
derived from the outer membranes of wild-type F. nucleatum
and the Fap2 mutant K50 and performed immunoblots with
TIGIT-Ig on protein lysates from these vesicles fractions. TIGIT
bound the wild-type F. nucleatum vesicles, whereas no binding
Figure 4. F. nucleatum Inhibits Primary NK
Cytotoxicity via TIGIT in an Hemagglutina-
tion-Dependent Manner
(A and B) NK cytotoxicity assays were performed on
35S-labeled 721.221 (A) and RKO (B) cells incubated
with or without F. nucleatum 726 (designated
721221+FN726 and RKO+FN726) and then incu-
bated with or without TIGIT-Ig or control Ig (C-Ig)
fusion proteins. The bacteria:cell ratio was 600:1.
The various cells were then incubated with primary
human NK cells for 5 hr and at various E:T ratios
indicated on the x axis. Figure shows one repre-
sentative experiment out of 2 performed. *p < 0.05
for 721.221 and RKO cells relative to cells with
F. nucleatum and TIGIT-Ig or control-Ig. The error
bars are derived from triplicates.
(C) YTS TIGIT cells were incubated with 721.221
cells that were pre-incubated or not with the clinical
F. nucleatum strains CTI-7 and CTI-2 isolated from
human colon adenocarcinomas. *p < 0.001. The
error bars are derived from triplicates.
(D) BW hTIGIT cells were incubated with the two
clinical strains CTI-7 and CTI-2 at bacteria: BW ratio
of 300:1. Mouse IL-2 in the supernatants was
determined by ELISA. *p < 0.05. The error bars are
derived from triplicates.
(E) Fifty microliters of human red blood cells (2% in
PBS) were incubated with 50 ml of two fold serial
dilutions (in PBS) of the indicated bacteria (original
O.D was 1). Hemagglutination was evaluated
following 120 min incubation at room temperature.
Figure shows one representative experiment out of
three performed.was detected in the vesicles from the Fap2-deficient K50 strain
(Figure 6C).
Lymphocytes within Tumors Express TIGIT and Are
Inhibited in a Fap2-Dependent Manner
Because TIGIT is expressed on T lymphocytes, as well as on NK
cells, we tested whether TIGIT is expressed in tumor infiltrating
lymphocytes (TILs) found within colon adenocarcinoma and
examined whether F. nucleatum inhibited the activity of these
TILs inaFap2-dependentmanner. TostainTIGIT in situ,wedevel-
opedanother TIGIT-specificmAb (#1) andstained frozensections
of human colon adenocarcinomas. We observed that the TILs
were broadly distributed throughout the colon adenocarcinoma
sections and that TIGIT was expressed on the vast majority of
TILs (Figure 7A). We next isolated the TILs from the colon adeno-
carcinomas and observed that NK cells constitute between 1%–
5% of all TILs and that around half of the CD3+ cells were CD8+
and half were CD4+. We also observed, in agreement with the
immunofluorescence microscopy data (Figure 7A), that the vast
majority of the TILs (NK, CD4+, and CD8+) express TIGIT (Fig-Immunity 42, 344–355ure 7B). However, because we were able
to recover only a small number of TILs, we
were unable to evaluate their functionality.
Because the F. nucleatum-mediated inhi-
bition of NK cell activities was observed
with all NK cells tested, we reasoned that
F. nucleatum would also inhibit T cell acti-vities, irrespective of their origin. Therefore, to test whether
F. nucleatum inhibits cytotoxic T lymphocyte (CTL) and T helper
cell activities, we used TILs obtained from melanomas, a tumor
type from which we have been able to isolate larger numbers of
viable TILs and generate TIL cell lines. TIL #14 isolated frommel-
anoma patient #14 is a CTL line that expresses TIGIT (Figure 7C).
Other TILs isolated from melanoma patients, both CD4+ and
CD8+, were also TIGIT positive. TIL #14 was incubated with the
melanoma tumor #14 in the presence or in the absence of the
various bacteria, and killing assays were performed. TIL #14
killing was inhibited in a Fap2-dependent manner, as moderate
inhibition was observed with the 726 strain and this inhibition
was abrogated in the absence of Fap2 (K50 mutant, Figure 7D).
The Fap2-mediated TIGIT inhibition was dependent on the hem-
agglutination activity of the bacteria. Strong inhibition (Figure 7D)
was observed with bacteria that caused efficient hemagglutina-
tion (Figure 4E and 5B), moderate inhibition (Figure 7D) was
observed with the 726 strain that caused moderate hemaggluti-
nation (Figure 5B), and no inhibition was observed with bacteria
that caused little or no hemagglutination (Figure 4E and 5B)., February 17, 2015 ª2015 Elsevier Inc. 349
Figure 5. Identification of Two Mutants
Defective in Their Ability to Inhibit Killing
and to Hemagglutinate Red Blood Cells
(A) YTS hTIGIT cells were incubated with 35S-
labeled 721.221 cells and with 721.221 cells that
were pre-incubated with or without the wild-type
F. nucleatum 726 (designated FN726) or with
mutants generated in the F. nucleatum 726
(designated with numbers, the two non-inhibitory
mutants K50 and D22 are designated with letters
and number). The bacteria to cells ratio was 600:1.
Incubation was performed for 5 hr at an E:T ratio
of 5:1. Figure shows several randomly selected
mutants. *p < 0.0005. The error bars are derived
from triplicates.
(B) Fifty microliters of human red blood cells (2% in
PBS) were incubated with 50 ml of two fold serial
dilutions (in PBS) of the indicated bacteria (original
O.D was 1). Hemagglutination was evaluated
following 120min incubation at room temperature.
(C) Flow cytometry of FITC-labeled wild-type 726
bacterium and mutants K50 and D22 binding to
721.221 cells. The bacteria to 721.221 ratio was
600:1. The left top dot plot shows 721.221 cells
without bacteria. The percentages of binding are
indicated in the figure. See also Figure S1. Fig-
ure shows one representative experiment out of
three performed.
(D) NK cytotoxicity assays were performed on 35S-
labeled 721.221 cells incubated without or with
F. nucleatum 726 (designated 721221+FN726) and
with the two mutants K50 and D22 (designated
721221+K50 and 721221+D22, respectively). The
bacteria to cell ratio was 600:1. The various cells
were then incubatedwith primary activated human
NK cells for 5 hr and at various E:T ratios indicated
on the x axis. Figure shows one representative
experiment out of three performed. *p < 0.005. The
error bars are derived from triplicates.
(E) BWhTIGIT cells were incubated with
F. nucleatum 726 and with the two F. nucleatum
mutants K50 and D22 at bacterium to BW ratio of
300:1. Mouse IL-2 in the supernatants was deter-
mined using ELISA. Figure shows one represen-
tative experiment out of three performed. *p <
0.0005. The error bars are derived from triplicates.We next tested whether F. nucleatum could inhibit the activity
of T cells present in the peripheral blood. Because TIGIT is
expressed on CD4+ memory T cells (Stanietsky et al., 2009),
we incubated lymphocytes obtained from donors that were
sero-positive or sero-negative for human cytomegalovirus
(HCMV), with pp65 overlapping peptides in the presence or in
the absence of the various F. nucleatum strains. Inhibition of
IFN-g secretionwas observedwith the Fap2-dependent bacteria
(726, and CTI-2, Figure 7E). Again, the efficacy of inhibition
correlated with the hemagglutination efficiency: moderate inhibi-
tion was observed with bacteria able to cause moderate hemag-
glutination (726, Figure 7E). Bacteria unable to hemagglutinate
(K50 or CTI-7, Figures 4E and 5B) showed little or no inhibition
of T cell activity (Figure 7E). No response was detected in donors
sero-negative for HCMV (Figure 7E).
We further tested whether the presence or absence of Fap2
affected NK cell activity indirectly via the secretion of cyto-350 Immunity 42, 344–355, February 17, 2015 ª2015 Elsevier Inc.kines from dendritic cells (DCs). We incubated DCs with the
726 strain, the 492 strain, or with the Fap2 inactivated strain
K50. There was equivalent secretion of IL-12 from the DCs,
regardless of the F. nucleatum used (Figure 7F). We also incu-
bated the cell culture supernatants of the DCs incubated with
the F. nucleatum strains with primary human NK cells and
observed a similar secretion of IFN-g and TNF-a (Figures 7G
and 7H, respectively). Thus, our data support that absence
of Fap2 does not affect DC production of IL-12 or DC-medi-
ated activation of NK cell-cytokine secretion and that the
Fap2 of F. nucleatum serves as a modulator of tumor cell
evasion by binding to TIGIT.
DISCUSSION
Immune evasion is a hallmark of cancer (Hanahan andWeinberg,
2011); however, whether bacteria within tumors provide tumors
Figure 6. TIGIT Interacts with the Fap2 Protein of F. nucleatum
(A) SDS PAGE gel of membrane proteins purified from the wild-type
F. nucleatum 726 strain and the two mutants: D22 and K50. The Fap2 protein
bands present in the wild-type F. nucleatum 726 is indicated by an arrow.
M represents the protein marker. The marker molecular weights are indicated
on the left.
(B) 0.53 106 F. nucleatum 726, the F. nucleatummutants K50 and D22 and the
CFT073UPECwere bound inwells of ELISA plates. Plateswere incubatedwith
human TIGIT-Ig or with human DNAM1-Ig (hDNAM1-Ig, incubated only with
FN726) and ELISA assays were performed. Figure shows one representative
experiment out of three performed. *p < 0.002. The error bars are derived from
triplicates.
(C) Outer membrane vesicle proteins extracted from the wild-type F. nuclea-
tum 726 and from K50 were run on a 7% SDS PAGE gel, transferred to a
nitrocellulose membrane and incubated with TIGIT-Ig. The molecular weights
protein markers are indicated on the left.immune evasion properties is unknown. There is a dichotomy in
the relationship between bacteria and cancer. In the early 1890s,
the surgeon William Coley used bacteria and bacterial extracts
to enhance anti-tumor immunity and successfully treated sar-
coma patients (Coley, 1910). Today, instillation of Mycobacte-
rium bovis Bacillus Calmette-Gue´rin (BCG) into the bladder is a
standard treatment for non-muscle invasive bladder cancer
(Grange et al., 2008). However, our data support that there mightbe bacteria found within tumors that facilitate a tumor’s ability
to evade immune cell attack. Bacteria found within tumors, for
example F. nucleatum, were shown to promote tumor prolifera-
tion and enhance tumor progression (Jobin, 2013; Sears and
Garrett, 2014). Herein, we have described and characterized a
mechanism by which the human colon adenocarcinoma-associ-
ated bacterium F. nucleatum facilitates a tumor’s evasion of the
immune system. We have shown that F. nucleatum bound tumor
cells and that F. nucleatum-containing tumors inhibited NK
cell cytotoxicity and tumor infiltrating lymphocyte cell activities
via the interaction of the F. nucleatum protein Fap2 with human
TIGIT.
F. nucleatum seems well-adapted to its host-species as
our human-derived F. nucleatum strains associated with human
but not mouse TIGIT. These results are in line with our previous
observations that hTIGIT manifests a broader recognition
pattern than mTIGIT. Human TIGIT recognizes both the mouse
and human PVR, whereas mTIGIT recognizes only mouse PVR
(Stanietsky et al., 2013; Stanietsky et al., 2009). The lack of
mTIGIT binding to F. nucleatum also explains prior observations
in mouse models wherein F. nucleatum’s interaction with NCR1
led to increased periodontitis (Chaushu et al., 2012).
Current microbiome surveys of human tumors support that
F. nucleatum is enriched in colon adenocarcinoma (Castellarin
et al., 2012; Kostic et al., 2012). We found that the vast
majority of TILs found within colon adenocarcinoma expressed
TIGIT. The TILs were broadly distributed throughout the tissue
sections and were not restricted to the specific sites in
which the bacteria were found. We further observed that
F. nucleatum can bind to many different tumor types in cell
line-based assays. In humans, F. nucleatummight have a special
tropism for human colon adenocarcinoma and its abundance in
the oral cavity might provide easy access to the gastrointestinal
tract. Perhaps microbiome surveys of other malignant tumors
will reveal an enrichment of F. nucleatum as well.
We observed only partial restoration of primary NK cell
cytotoxicity when we used TIGIT-Ig to block F. nucleatum-TIGIT
interactions. Killing might only have been partially restored
with TIGIT-Ig because this reagent does not efficiently block
F. nucleatum-TIGIT interactions. Indeed, in the absence
of Fap2, inhibition of NK cell cytotoxicity was abrogated
completely.
Wewere unable to use a blocking anti-hTIGITmAb that we had
previously generated, because this mAb was unable to block the
F. nucleatum-TIGIT interaction. This result suggests that TIGIT
interacts with F. nucleatum at a binding site distinct from that
of hPVR. However, we did observe that the inhibition of NK cell
cytotoxicity wasmediated via the same signaling motifs required
for the inhibition of TIGIT by PVR. Other PVR binding receptors
such as DNAM1 did not interact with F. nucleatum.
Using transposon-based mutagenesis we found two
F. nucleatum mutants that could not inhibit killing by YTS TIGIT
cells. The transposon was inserted in the fap2 gene and using
NK cytotoxicity assays, BW reporter assays, ELISA-based bind-
ing assays, and Western blotting, we found that TIGIT interacts
with Fap2.
The Fap2 protein undoubtedly possesses functions beyond
hTIGIT binding. Indeed, we found that Fap2 is involved in the
binding of F. nucleatum to cell lines such as K562 and RKO. InImmunity 42, 344–355, February 17, 2015 ª2015 Elsevier Inc. 351
Figure 7. F. nucleatum Inhibits T Cell Activity
(A) Immunofluorescencemicroscopyof frozen sections derived fromcolon adenocarcinomas stainedwith anti-TIGITmAb#1 (green) andDAPI (blue). Scale 100mm.
(B) Tumor infiltrating lymphocytes were isolated from colon adenocarcinomas. The figure shows TIGIT expression (empty histograms) on the indicated tumor
infiltrating lymphocytes: T cells, CD4+ T cells, CD8+ T cells, and NK cells. The filled histogram represents staining with control antibodies (APCconjugated for the T
and NK cells and FITC-conjugated for the CD4+ and CD8+ cells). The backgrounds were set on the entire lymphocyte population including both T and NK cells.
(legend continued on next page)
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addition, we observed that Fap2 is involved in F. nucleatum-
mediated hemagglutination, in co-aggregation with other bacte-
ria, and in placental colonization in mice (Coppenhagen-Glazer
et al., 2015). The hemagglutination potency of Fap2 directly
correlated with TIGIT inhibition. Furthermore, the 726 bacterium
showed unstable hemagglutination properties and sometimes
after few passages in culture lost its hemagglutination ability.
In these situations, no TIGIT inhibition was observed. Going for-
ward, it will be interesting to determine the exact Fap2 domain(s)
involved in hemagglutination and TIGIT inhibition, to investigate
why strains vary in hemagglutination, and to precisely under-
stand how F. nucleatum hemagglutination activity is related to
F. nucleatum Fap2-TIGIT interactions.
F. nucleatum undoubtedly possesses other molecules that
canmediate its binding to host cells. In support of this idea, there
is the Fusobacterium adhesin, FadA (Xu et al., 2007), as well as
our observations that binding of Fap2 mutants to 721.221 cells
was similar to that of the wild-type F. nucleatum and both wild-
type and mutant F. nucleatum strains bound TIGIT-negative
human cell lines.
In summary, we have identified a tumor-based immune
evasion mechanism that is bacteria-dependent, wherein
F. nucleatum bound tumors are protected from NK-mediated
killing and immune cell attack due to an interaction between
the fusobacterial protein Fap2 with the immune cells inhibitory
receptor TIGIT.EXPERIMENTAL PROCEDURES
Primary Human NK Cells, TILs, DC, Cell Lines, Fusion Proteins, and
Antibodies
Primary human NK cells were isolated from PBLs of healthy donors, using
the human NK cell isolation kit and the autoMACS instrument according to
the manufacturer’s instructions (Miltenyi Biotec). NK cell purity was 99% as
determined by positive CD56 and NKp46 expression and negative CD3
expression. DCs were generated as previously described (Verbovetski et al.,
2002). Melanoma tumor lines and TILs were obtained from patients as previ-
ously described (Besser et al., 2013). IRB approval and patient consent to
obtain human tumor tissue was obtained. Use of human samples was
approved by the IRB of Harvard Medical School, Tel Hashomer Hospital,
and Hadassah Medical School. The following cell lines were used: the human
EBV transformed 721.221 cells, the human colorectal line RKO, the human
erythroleukemia line K562, the mouse thymoma BW cells and the NK tumor
cell line YTS ECO. The generation of the various YTS ECO transfectants YTS
hTIGIT, YTS STOP 190, and YTS STOP 231 cells was described previously
(Stanietsky et al., 2009). The generation of the BW transfectants BW hTIGIT,
BW mTIGIT, and BW NKp30 was described previously (Stanietsky et al.,
2013; Stanietsky et al., 2009). All cells, except from the human primary NK
cells, were grown in RPMI medium supplemented with 10% FCS. Human
NK cells were grown in the presence of 10% human sera, supplemented(C) Characterization ofmelanoma tumor-derived TIL #14. TIL-14was stainedwith
control antibodies.
(D) TIL #14 cytotoxicity assays were performed on 35S-labeled autologous melan
x axis. The bacteria:cell ratio was 600:1. The E:T ratio was 5:1. *p < 0.05. The er
(E) Lymphocytes isolated from CMV positive and CMV negative donors (indicate
peptides and with or without the bacteria as indicated on the x axis. Incubation wa
*p < 0.005. The error bars are derived from triplicates.
(F) DC were incubated with or without the F. nucleatum strains indicated on the x a
by ELISA 48 hr later. The error bars are derived from triplicates.
(G and H) The supernatants obtained from (F), indicated on the x axis, were incu
supernatants was determined 48 hr later. The error bars are derived from triplicawith human IL-2. The generation of TIGIT-Ig, the blocking anti-TIGIT mAb
#4, and the control-Ig fusion proteins was previously described (Stanietsky
et al., 2013; Stanietsky et al., 2009). The following commercial antibodies
were used: anti-mouse TIGIT (FAB7267A, R&D systems), anti-NKp30 (clone
P30-15, Biolegend), and anti-human PVR (MAB25301, R&D systems).
Bacterial Strains and Growth Conditions
F. nucleatum strains were grown in Wilkins Chalgren broth (Oxoid) or on
Columbia agar plates (Oxoid, UK) supplemented with 5% defibrinated sheep
blood (Novamed) in an anaerobic chamber (Bactron I-II Shellab) in an atmo-
sphere of 90% N2, 5% CO2 and 5% H2 at 37
C. Escherichia coli were grown
in LB broth (Difco) or on LB agar plates (Difco), under aerobic conditions at
37C. All antimicrobials used in this study were purchased from Sigma-Aldrich
Israel. Antibiotic concentrations were as follows: ampicillin 100 mg ml1, chlor-
amphenicol 30mg ml1, and thiamphenicol 5mg ml1. For fusobacteria, broth
was supplemented with half concentrations. Clinical tumor isolates (CTI)
were isolated from human colon adenocarcinomas. Tumors were resected
and a portion of the tumor was placed in tryptic soy broth with 0.05%
cysteine-hydrochloride. Tumors were disaggregated and the tissue was
plated on Fastidious Anaerobe agar plates supplemented with josamycin,
vancomycin, and norfloxaxin (3,4, and 1 mg/ml, respectively). Colonies were
streaked for re-isolation on Columbia agar and subjected to Gram-staining
before 16S rRNA gene based sequencing for identification. F. nucleatum
CTIs have been deposited at BEI resources repository (http://www.
beiresources.org/). Transposon mutagenesis of F. nucleatum and the deter-
mination of the transposon insertion site in the fusobacterial genome was per-
formed as recently described (Coppenhagen-Glazer et al., 2015).
FITC Labeling of Bacteria and Binding to Cells
F. nucleatum (109 CFU/ml) was labeled with fluorescein isothiocyanate (FITC)
(0.1 mg/ml in PBS; Sigma-Aldrich) for 30min at room temperature and washed
three times in PBS. FITC labeled bacteria were incubated with various cells
at various bacteria to cell ratios for 30 min at 4C. Cells were washed and bac-
terium binding was detected using flow cytometry.
Killing Assays
Target cells were grown overnight in the presence of 35S-Methionine added to
a methionine-free media (Sigma). Prior to incubation with the effectors cells
(either TILs or NK cells), cells were washed, counted, and 5,000 cells/well
were plated. When target cells were coated with bacteria, the bacterial-to-
target ratio was 600:1. When fusion proteins were included in the assays,
each well received 5 mg of the appropriate protein. When antibodies were
included, each well received 0.5 mg of mAb. For each target, the spontaneous
35S release was calculated using cells, which were not incubated with effector
cells, and maximum [35S]-release was calculated by applying 100 ml 0.1 M
NaOH to the target cells. The amount of [35S]-release was measured after
5 hr of incubation with effectors (at 37C) by aMicroBeta2 2450 (Perkin Elmer).
The cytotoxicity of themelanoma TILs was determined after 12 hr of incubation
with their appropriate targets. The maximum and spontaneous release of 35S
did not change in the presence or in the absence of the various bacteria.
BW Assays
The various bacteria were placed in 96 well plates and incubated for 1 hr at
37C in medium containing RPMI supplemented with 10% FCS and peni-
cillin-streptomycin. Subsequently, cells (50,000 of the appropriate BW ormAbs as indicated in the figure. The filled histogram represents the stainingwith
oma #14 cells incubated without or with the various bacteria indicated on the
ror bars are derived from triplicates.
d on the x axis), were incubated with or without a mixture of pp65 overlapping
s performed for 48 hr and IFN-g in the supernatants was determined by ELISA.
xis at a bacteria to DC ratio of 100:1. IL-12 in the supernatants was determined
bated with primary NK cells and the presence of IFN-g (G) or TNF-a (H) in the
tes.
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BW transfectants) were added and incubated together with the bacteria for
48 hr at 37C, 5% CO2. The final cell to bacteria ratio was 1:300. Next, super-
natants were collected and the presence of mouse IL-2 in the supernatants
was determined using standard ELISA assay.
T Cell Proliferation Assays
T cells were isolated from peripheral blood of CMV-positive and CMV-negative
people. 100,000 T cells were plated in each well of 96 round bottom plates
incubated with 0.6 mg dissolved in 50% DMSO (in PBS) of pp65 overlapping
peptides PepMix HCMVA (pp65), (JPT Peptide Technologies), in the presence
or in the absence of various bacteria (bacteria-to-target ratio was 300:1).
Plates were incubated for 48 hr and then the presence of IFN-g in the cell
culture supernatants was determined by ELISA.
IL-12 Secretion from DCs following Bacteria Stimulation
DCs were isolated from peripheral blood as described above. 100,000 T cells
were plated in each well of 96 round bottom plates incubated in the presence
or in the absence of various bacteria, at various bacteria to DC ratios. Plates
were incubated for 48 hr and then the presence of IL-12 in the cell culture
supernatants was determined by ELISA.
ELISA Assays for Direct TIGIT Binding
Various bacteria (0.53 106 per well) were incubated overnight in 100 ml of bind-
ing solution (0.1 M Na2HPO4, pH 9). Plates were then blocked with 2% milk in
PBS, washed, and incubated for 2 hr with TIGIT-Ig proteins (3 mg protein per
well). Binding of the Ig fusion protein was detected using biotinylated anti-hu-
man antibodies (the TIGIT-Ig fusion protein is composed of the extracellular
portion of human TIGIT fused to human IgG1 (Stanietsky et al., 2009). ELISA
assays were performed with streptavidin-HRP.
Immunofluorescence Staining
Slides were defrosted and fixated in 4% PFA. Samples were permeabilized
with 0.1% Triton in PBS, washed, and blocked in Cas BlockTM (Invitrogen)
at room temperature. Slides were then incubated with primary anti-TIGIT anti-
body (mAb #1, in-house prepared, 1:10 dilution) overnight and then were incu-
bated with Alexa-Fluor 647 conjugated goat anti-mouse antibodies directed at
the IgG (H+L) part of the primary antibody. Nuclear staining was performed us-
ing DAPI staining according to manufacturer protocol (Sigma-Aldrich).
Outer Membrane Vesicle Preparation
Four-day-old F. nucleatum cultures were harvested by centrifugation at
10,0003 g for 20 min at 4C. Culture supernatants were collected and filtered
through a 0.2 mm filter (Whatman Schleicher & Schuell). Cell-free supernatants
were centrifuged at 100,000 3 g for 2 hr. The supernatant was discarded
and the pellet containing the vesicles was washed twice with Tris-buffered
saline (TBS, 0.05 M Tris-HCl [pH 7.8], 0.1 M NaCl) by centrifugation at
100,000 3 g. The pellet was stored at 20C until further use.
SUPPLEMENTAL INFORMATION
Supplemental Information includes one figure and can be found with this
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